EULAR Points to Consider for the Diagnosis and Management of Rheumatic Immune-Related Adverse Events Due to Cancer Immunotherapy With Checkpoint Inhibitors

Annals of the Rheumatic Diseases - United Kingdom
doi 10.1136/annrheumdis-2020-217139

Related search